AM Pharma
  • Home
  • About Us
    • About AM-Pharma
    • Management Team
    • Supervisory Board
    • Careers
  • Our approach
    • Our Product and MOA
    • Acute Kidney Injury (AKI)
    • Our AKI Pipeline
      • SA-AKI
      • COVID-19 and AKI
      • CKD and AKI
      • CSA-AKI
  • Partnering
  • Investors
  • Media Centre
    • Press Releases
    • Publications
  • Contact
  • Menu Menu

Home > Programs > Inflammatory Bowel Disease (IBD)

Inflammatory Bowel Disease (IBD)

Inflammatory Bowel Disease (IBD) is a group of disorders that is associated with inflammation, most commonly in the small and large intestine (colon). The two major types of this disorder are Crohn’s disease and Ulcerative Colitis (UC), which occurs in the colon and is characterized by ulcers (open, painful wounds). The main symptoms of UC are gradual onset of severe diarrhea mixed with blood, cramps, high fever and peritonitis.

AM-Pharma’s proprietary alkaline phosphatase (AP) therapeutics are disease modifying therapeutics. AP is an enzyme that is naturally present in the human body and is located on epithelial cells of the gastrointestinal tract, kidney, liver and lungs. AP expression in the gut is reduced in patients with UC.

For UC, recAP is being developed as an oral formulation.

Background information on the role of alkaline phosphatase in IBD:

Tuin et al, Gut 2009

Market and opportunity

The incidence of UC in the Western market is around 1.5 million patients, of which 60% have a moderate-to-severe form.

For patients failing first line treatment with 5-ASA there is a need for therapies that are safe, remain efficacious over time and are convenient to use.

As a potential biologic treatment, Alkaline Phosphatase (AP) would provide three key differentiating features:

Oral delivery

increasing patient compliance

Reduced safety risks

Potentially a faster onset of action

Clinical trials

Results from Phase I and Phase II clinical trials, with administration of bovine AP by duodenal drip, showed its potential as a tolerable and efficacious treatment for UC.

Bovine AP Phase II

AM-Pharma conducted an open-label, multi-center trial, administering bovine AP continuously for 7 days. The trial recruited 21 moderate-to-severe UC patients who were unresponsive to treatment with steroids and immune suppressants.

The Mayo score showed a significant decrease in patients receiving AP, versus baseline, at Day 21, and the MTWSI score at Day 21 and Day 63.

In addition, the trial showed there were no clinically relevant adverse events causing withdrawal or considered serious, nor laboratory abnormalities nor antibody formation against AP.

Background information on the Phase II study results:

Lukas et al, Inflamm Bowel Dis. 2010

  • Privacy Policy
© AM-Pharma B.V.
Website by BTTR
linkedin
Scroll to top

We use cookies to help us improve our website by collecting and reporting information on how you use it. For more information about how we use cookies please see our Cookies Policy

AcceptReject


How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visit to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Other cookies

The following cookies are also needed - You can choose if you want to allow them:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Policy
Accept settingsHide notification only